Angle Share Price (AGL)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Angle Plc	LSE:AGL	London	Ordinary Share	GB0034330679	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.50	0.63%	79.50	196,441	16:08:14

Bid Price		Offer Price	High Price	Low Price	Open Price
79.00		80.00	79.50	79.00	79.00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.68	-10.87	-6.56		137

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
16:30:57	O	35,000	80.00	GBX

Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Agronomics (ANIC), Valirx (VAL)

Angle (AGL) Latest News

Angle News

Date	Time	Source	Headline
08/10/2019	07:00	UKREG	Angle PLC Notice of AGM
04/10/2019	17:54	UKREG	Angle PLC Holding(s) in Company
04/10/2019	08:58	ALNC	Angle Notes Queen Mary University's European Cancer Prognosis Patent
04/10/2019	07:08	ALNCF	Alliance News Flash Headline
04/10/2019	07:00	RNSNON	Angle PLC European patent granted for megakaryocyte analysis
13/9/2019	07:00	RNSNON	Angle PLC Use of Parsortix in head and neck cancer
10/9/2019	07:01	UKREG	Angle PLC Research with Parsortix in prostate cancer
04/9/2019	14:09	ALNC	Angle Reports Positive Study Results For Parsortix System
04/9/2019	07:01	RNSNON	Angle PLC Parsortix for Neuroendocrine Analysis in SCLC
29/8/2019	10:57	ALNC	Angle Ovarian Cancer Testing Platform Study Enrols First Patients

More Angle News

Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date	Time	Title	Posts
16/10/2019	11:28	ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY	1,639
28/2/2019	12:22	ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET	11,356
28/8/2018	12:29	ANGLE plc (AGL) One to Watch	-
02/7/2018	12:06	Still time to look at Angle (AGL)	-
14/5/2018	09:44	ANGLE (AGL) Strategic Move	-

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-10-17 17:30:57	80.00	35,000	28,000.00	O
2019-10-17 15:30:48	80.00	29,444	23,555.20	O
2019-10-17 14:30:41	79.56	4,000	3,182.40	O
2019-10-17 14:03:59	78.75	6,746	5,312.48	O
2019-10-17 13:01:44	80.00	50,000	40,000.00	O

View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Date	Subject
17/10/2019 09:20	Angle Daily Update: Angle Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 79p. Angle Plc has a 4 week average price of 75.80p and a 12 week average price of 66.50p. The 1 year high share price is 85.50p while the 1 year low share price is currently 38p. There are currently 172,754,816 shares in issue and the average daily traded volume is 106,556 shares. The market capitalisation of Angle Plc is £137,340,078.72. Read Full Thread Reply
04/10/2019 08:14	sicilian_kan: The option agreement expires in just 20 months. Would be interesting to know the terms - how much AGL need to pay to exercise the option agreement. The extent of the payment required could have both a positive and a negative impact on the share price, depending on the amount. As ever from AGL, we only get part of the story. A shame because the news is actually good. Read Full Thread Follow Reply
12/9/2019 09:26	sicilian_kan: The problem here is the market cap, which is already very high. There are 172,754,816 shares in issue and a further 20,555,806 options in place. So the market cap at today’s price is already £136m. Fully diluted it is £153m. That is a lot for a company with a poor sales track record (missing all their initial targets) and without FDA approval. Yes FDA approval would help the share price significantly, but if the FDA in examining the data wanted a further trial, shareholders could have 50% of their investment wiped out overnight. So there are risks and at the moment Newland has not released the data on the MBC trial just the fact of the endpoint being met (and the need for further analytical studies). Without that data or the reasons for the analytical studies or confirmation of their success, shareholders can not properly assess the likely strength of any FDA application and there remains, as bones sets out, significant risk in the FDA process re timing and requirements. Would not be surprised if the share price will pull back 5-12p or so as the (justified) excitement fades over the prostate news and media reporting. Read Full Thread Follow Reply
06/5/2019 15:59	alloa2003: I think the AGL share price is starting to reflect the potential value based on the risk that it may or may not be realised. For example if the potential value was £2 a share (based on profit, pe ratio, etc) and the chance of being successful was deemed 80% then you would expect the price to be much closer to £2. It is a form of arbitration with the share price reflecting the risk/reward factor compared to potential "fair value". Read Full Thread Follow Reply
22/4/2019 23:29	sicilian_kan: If the MBC trial is not, on the existing data (however confident one is) a nailed on certainty, surely the next questions are: 1) What is the best estimate probability of commercial data appearing in the MBC trial? 2) What share price spectrum might arise if the trial demonstrates commercial data? 3) What share price spectrum might arise if the trial does not demonstrate commercial data? Then an investment strategy can be formulated. There is far too little analysis of the actual MBC data that is available. There is also far too little analysis on here of the chance of success and on the share price gains and falls that might occur upon the MBC trial data being released. Read Full Thread Follow Reply
18/4/2019 09:00	alloa2003: There has been a sea change in the AGL share price of late, no highs then sharp reversals on announcements and no drifting on a lack of news. There is strong underlying demand for the shares which leads me to believe things are afoot behind the scenes. Read Full Thread Follow Reply
10/4/2019 09:46	sicilian_kan: At 70p, AGL's fully diluted market cap is £126m. 143,486,522 shares in issue, plus 20,555,806 options etc. = 164,042,328 shares fully diluted. This might see a 75p top before news, but quite frankly, the current share price is way overvalued given the risk involved, the laborious process involved (see youtube video) and the likely revenues from MBC. Given the hype around AGL, I think on good news 100-150p could be hit. On bad MBC results, we are looking at 10p-35p depending on how bad the results are. Results could also be mixed. So short term upside of 50-100%, short term downside potential of 50-80%. Chance of success, say 80-85%? I bear in mind that the ovarian trial was disappointing relative to the earlier study results. With significant downside possibility, I would expect a risk reward ratio of at least 3:1 to make this attractive. Fair price circa 50-55p? For those in at that level, it is definitely worth a hold, but I do not see buying in at the current share price as being in any way attractive. Read Full Thread Follow Reply
29/1/2019 10:20	semper vigilans: As usual a decent bit of research from a large, highly reputable organisation working in the right field, is not really recognised by the market. Whatever one thinks of false starts earlier, at some stage the build up of published, independent research must give the AGL share price a decent, upward shove? Read Full Thread Follow Reply
06/12/2018 10:46	alloa2003: Brexit is not helping sentiment but not the reason for AGL share price weakness. There is literally no interest in the stock at the moment - going to be news driven for some time to come until we see sales and profits. Might drift until it finds support. Read Full Thread Follow Reply
26/3/2018 09:17	alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off. Read Full Thread Follow Reply
24/12/2017 11:06	alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :) Read Full Thread Follow Reply

Angle share price data is direct from the London Stock Exchange

Your Recent History

LSE

AGL

Angle

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20191018 00:31:19